This meta-analysis pooled the incremental net benefit (INB) of marketed RSV vaccines against no vaccination. Of 17 model-based evaluations, all from high-income settings, 11 entered random-effects meta-analyses run separately by population. In older adults the pooled INB was USD 105.05 (95% CI 41.89–168.21). It stayed positive when any one study was left out. For infants, via maternal vaccination, it was USD 5.81 (95% CI −35.44 to 47.07), sensitive to study exclusion. Heterogeneity was high (I² 93.2% and 89.4%), and no study came from low- or middle-income countries.
Why it is interesting: Pooling net benefit rather than cost-effectiveness ratios lets economic evaluations be combined on one monetary scale. Among older adults, strategies targeting older ages or higher-risk groups gave higher net benefit than broad age-based programmes.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.